Can I Take Calcium With PT-141 (Bremelanotide)?
At a glance
- Drug / bremelanotide, FDA-approved as Vyleesi [1]
- Form and dose / 1.75 mg subcutaneous autoinjector [1]
- Approved use / premenopausal women with acquired, generalized HSDD [1]
- Calcium / commonly sold as calcium carbonate or calcium citrate supplements [2]
- Calcium in label interactions / not named [1]
- Label oral-medicine warning / may slow gastric emptying and reduce absorption of oral medicines [1]
- Main label safety issues / transient blood pressure increase, nausea, flushing, headache [1]
What is PT-141 (bremelanotide)?
Bremelanotide is a melanocortin receptor agonist approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) [1]. It is a 1.75 mg subcutaneous injection given at least 45 minutes before anticipated sexual activity and no more than once in 24 hours; using more than eight doses per month is not recommended [1]. The label says it is not indicated for men or postmenopausal women and not for enhancing sexual performance [1]. The mechanism by which it improves HSDD is unknown [1]. PT-141 products sold as compounded or research-use peptides are not Vyleesi and are not FDA-approved drugs [3][1].
Does calcium interact with bremelanotide?
The Vyleesi drug interactions section names oral naltrexone and a general effect on oral medicines; calcium is not named [1]. The label's general warning is that bremelanotide may slow gastric emptying and has the potential to reduce the rate and extent of absorption of concomitantly administered oral drugs [1].
What does the label say about oral medicines?
The label says to avoid Vyleesi with oral drugs that depend on threshold blood concentrations for efficacy, such as antibiotics, and to consider skipping Vyleesi when a quick onset of an oral medicine's effect is wanted, such as indomethacin for pain relief [1]. In clinical pharmacology studies, only naltrexone and indomethacin were meaningfully affected [1]. The label says to avoid Vyleesi with oral naltrexone-containing products used for alcohol or opioid addiction because of the severe consequence of naltrexone treatment failure [1].
What does bremelanotide do to blood pressure?
Bremelanotide transiently increases blood pressure and reduces heart rate after each dose [1]. In clinical studies, the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate down up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. In an open-label ambulatory study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic and 1.7 mmHg diastolic, with a mean heart rate decrease of 0.5 beats per minute [1].
The label contraindicates Vyleesi in uncontrolled hypertension or known cardiovascular disease and says it is not recommended for patients at high risk for cardiovascular disease [1]. It also says to assess cardiovascular risk and ensure blood pressure is well controlled before starting and periodically during treatment [1].
If you take calcium with levothyroxine or Cipro
Calcium has well-known interactions with some oral drugs. In a study of 8 healthy adults, 500 mg elemental calcium as carbonate, citrate or acetate each reduced single-dose levothyroxine absorption by about 20% to 25% [6]. The Cipro label says to take ciprofloxacin at least 2 hours before or 6 hours after products containing calcium; it may be taken with a meal that contains dairy [7]. These are timing rules between calcium and those oral drugs; the Vyleesi label gives no calcium timing rule [1].
Practical answer
The Vyleesi label does not name calcium or give any separation time for it [1]. Its own timing rules concern the injection itself: at least 45 minutes before anticipated sexual activity, and no more than one dose in 24 hours [1]. The label says the duration of effect after a dose is unknown [1].
What to watch for
The label lists nausea, flushing, injection site reactions, headache and vomiting as common adverse reactions. In the 24-week trials, nausea occurred in 40.0% of Vyleesi patients vs 1.3% on placebo, flushing in 20.3% vs 0.3%, injection site reactions in 13.2% vs 8.4%, headache in 11.3% vs 1.9%, and vomiting in 4.8% vs 0.2% [1]. Nausea led 8% of Vyleesi patients to stop the trials [1]. Focal hyperpigmentation was reported by 1% of patients using up to 8 doses per month [1]. The label says to consider discontinuing Vyleesi if hyperpigmentation develops [1].
Frequently asked questions
Can I take calcium with PT-141?
Does calcium make PT-141 less effective?
Do I need to wait 2 hours between calcium and PT-141?
Does calcium increase the PT-141 blood pressure effect?
Is compounded PT-141 the same as Vyleesi?
What if I take levothyroxine with calcium?
References
Show all 8 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- Straub DA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract. 2007;22(3):286-96.
- Official web page.
- Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691.
- Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040.
- Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid. 2011;21(5):483-6.
- U.S. National Library of Medicine, DailyMed. Cipro (ciprofloxacin) (ciprofloxacin hydrochloride) prescribing information. Cipro (ciprofloxacin) (ciprofloxacin hydrochloride) label
- U.S. Food and Drug Administration.